Content thumbnail Quest Diagnostics Corporate Responsibility Report
AI Content Chat (Beta) logo

2021 CORPORATE RESPONSIBILITY REPORT I 60 EXPANDING CAPACITY Quest collaborations on the cutting edge We enter into collaborations to broaden access to key tools and insights that can improve outcomes for patients. These important relationships expand resources and access to innovative technologies. GRAIL Galleri ® multi-cancer early detection blood test By providing specimen collection assistance for this test, we are helping patients receive broader access to a unique solution with potentially life-saving implications, as early detection is crucial to optimize outcomes. Zora Bioscience Ceramide-analysis technology Using technology licensed from Zora, we will be developing a test service identifying risk in patients with stable coronary heart disease and acute coronary syndrome independent of LDL-cholesterol status. Patients at highest risk for CVD-related death will be able to work with their healthcare team on more aggressive preventive measures. Biocept Target Selector ™ Next-Generation Sequencing (NGS) Lung Panel Based on technologies from Biocept and ThermoFisher Scientific, this collaboration will provide access to this liquid biopsy test to more patients nationwide. The panel provides physicians with therapeutic options for patients with non–small cell lung cancer and enables Quest to provide crucial insights in tissue biopsy in a less invasive manner. Agilent Technologies Inc. Early breast cancer Ki-67 companion diagnostic As part of our long-standing precision medicine collaboration with organizations like Agilent, we added testing that identifies whether patients with early breast cancer have the Ki-67 protein in malignant tumor cells. The test helps confirm whether a patient with a specific “triple positive” breast cancer with high risk of recurrence may benefit from treatment with standard endocrine therapy plus abemaciclib, an immunotherapy checkpoint inhibitor offered by Eli Lilly and Company as Verzenio. It is the sole FDA-approved drug in this class for these patients. Working with Paige to improve cancer diagnosis with artificial intelligence In May, Quest announced a collaboration with Paige, a New York-based company with machine-learning expertise in pathology diagnostic data. Visual inspection of tumor tissue using a microscope to detect cancer can be revolutionized by artificial intelligence (AI)–enabled computational pathology. By identifying known patterns in tissue that characterize disease, as well as identifying new markers, AI-assisted digital pathology enables deeper examination and easier collaboration. The project combines Quest's leadership in pathology and national scale with Paige's leading AI-based software capabilities. In September, the FDA authorized the first use of Paige’s AI tools for assistance in diagnosing prostate cancer. Quest Diagnostics began using Paige Prostate in October. TABLE OF CONTENTS 2021 OVERVIEW COVID-19 RESPONSE PROMOTING A HEALTHIER WORLD CREATING AN INSPIRING WORKPLACE BUILDING VALUE REFERENCES

Quest Diagnostics Corporate Responsibility Report - Page 60 Quest Diagnostics Corporate Responsibility Report Page 59 Page 61